KDM1A and small cell lung carcinoma: Similar findings were validated in SCLC, where inhibition of LSD1 using ORY-1001 and bomedemstat both increased MHC-I expression to promote the effects of anti-PD-1 and PD-L1 antibody therapy, respectively [144, 199].